Key facts
- It has raised $1.3M; the latest was Early Stage VC ($1.3M) in May 2025.
- Notable investors include Qiming Venture Partners, GL Ventures, CICC Capital, Roche Accelerator, The Innovation and Technology Commission.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for BayOmics
- ·The full record, as it builds
Funding rounds
No funding rounds for BayOmics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BayOmics
Manufacturer of proteomic sample processing and spatial analysis technologies intended for biomedical and pharmaceutical research. The company offers high-throughput automation, nano-scale protein preparation, and spatial visualization capabilities using proprietary centrifuge-based tip systems and patented workflows, serving life science researchers and drug developers to conduct high-sensitivity mass spectrometry, analyze tissue microenvironments, identify biomarkers, and explore cell-type specific interactions and therapeutic targets across various disease models with improved reproducibility, scalability, and analytical depth.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2022
- Website
- bayomics.com/
- Ownership
- Privately Held (backing)
BayOmics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BayOmics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BayOmics in its N-PORT filings yet. We sweep new filings monthly.